

Hermona Soreq

- The Hebrew University of Jerusalem, The Edmond and Lily Safra Center for Brain Sciences and The Department of Biological Chemistry
- The Alexander Silberman Institute of Life Sciences, The Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401 ISRAEL; ORCID: 0000-0002-0955-526X

Curriculum vitae

- | | | | |
|--|-----------------------|---------|-------------------|
| • The Weizmann Institute of Science, Rehovot, Israel | PhD | 06/1976 | Biochemistry |
| • Rockefeller University, NYC | Post-Doctoral Studies | 08/1979 | Molecular Biology |

Scientific activities, honors, awards

• Academic Positions:

- | | |
|-------------|--|
| 2010- | The Edmond and Lily Safra Center for Brain Sciences (ELSC), founding member |
| 2005 - 2008 | Elected Dean, Faculty of Mathematics and Natural Sciences, The Hebrew University |
| 2000 -2005 | Head, The Eric Roland Center for Neurodegenerative Diseases, The Hebrew University |
| 1995 - 1999 | Head, the Alexander Silberman Institute of Life Sciences, The Hebrew University |
| 1992 -1995 | Head, Dept. of Biological Chemistry, The Hebrew University |
| 1989 - On | Professor of Molecular Neuroscience, Department of Biological Chemistry, Hebrew University |
| 1986 - 1988 | Associate Professor of Molecular Neuroscience, The Hebrew University of Jerusalem. |
| 1983 – 1986 | Associate Professor, Neurobiology Department, Weizmann Institute |
| 1979 - 1983 | Senior Scientist, Neurobiology Department, Weizmann Institute |
| 1977 – 1979 | Fogarty Fellow, Department of Molecular Cell Biology, The Rockefeller University. |

• Awards

- | | |
|-----------|---|
| 2022 | The EMET Prize. Sponsored by the A.M.N. Foundation for the Advancement of Science, Art and Culture in Israel, under the auspices of and in cooperation with the Prime Minister of Israel. |
| 2017 | Ilanit-Katzir Prize for exceptional achievements in the Life Sciences |
| 2016 | PsychoNeuroInflammation Society (PNIRS) award |
| 2015 | The Rappaport Prize for Bio-Medical research |
| 2014-2019 | •Cluster of Excellence NeuroCure guest at the Charité-Universitätsmedizin, Berlin
•Israeli National Center of Excellence (I-Core) on Trauma, member of leadership team |
| 2009 | •The Lise Meitner Alexander von Humboldt Foundation Award, Germany
•Miller Fellowship, University of California, Berkeley |
- Honorary Doctorates in Erlangen (2007), Beer-Sheva (2007), Stockholm University (1996).
2006 Teva's Founders Award in Molecular Medicine; Landau Prize for Biomedical Research

Selected ongoing funding / projects

- 5P01AG014449-21 (**NIH-NIA**) Mufson (Project Leader), Role: sub-award, co-investigator Project period: 01/03/20-28/02/2025 Neurobiology of Mild Cognitive Impairment in the Elderly. Amount: 235,000 Euro
- 3213/19 (**Israel Science Foundation**) Soreq (Co-PI) Project period: 01/10/2019-30/09/2023 Neuronal hyperactivity in prodromal Alzheimer's disease. Amount: 132,000 Euro
- 1016/18 (**Israel Science Foundation**) Soreq (PI) Project period: 01/10/2018-30/09/2023 Exploring the impact of Cholinergic non-coding RNA on anxiety and metabolic disorders. Amount: 480,000 Euro
- **Keter Holdings** Soreq (PI) 01/01/2022-31/12/2023 Hyperbaric modulation of small RNA regulators in aged individuals. Amount: 440,000 Euro

Selected publications

- Yayon et al., High-throughput morphometric and transcriptomic profiling uncovers composition of naïve and sensory-deprived cortical cholinergic VIP/CHAT neurons. **EMBO J**, 2022. In press
- Winek, K., et al., Transfer RNA fragments replace microRNA regulators of the cholinergic poststroke immune blockade. **Proc Natl Acad Sci U S A**, 2020. 117(51): p. 32606-32616.
- Hanan, M., et al., A Parkinson's disease CircRNAs Resource reveals a link between circSLC8A1 and oxidative stress. **EMBO Mol Med**, 2020. 12(9): p. e11942.
- Simchovitz, A., et al., NEAT1 is overexpressed in Parkinson's disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. **FASEB J**, 2019. 33(10): p. 11223-11234.
- Lobentanzer, S., et al., Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokinin Interface in Schizophrenia and Bipolar Disorder. **Cell Rep**, 2019. 29(3): p. 764-777 e5.

Patents

- **Downregulating miR-132 for the Treatment of Lipid Related Disorders**. United States. 10,174,320. 2015/09/21. Patent Status: Granted/Issued. Year Issued: 2019
- **Ache Antisense Deoxyoligonucleotide As Anti-Inflammatory Agent**. United States. 8,722,876. 2004/05/26. Patent Status: Granted/Issued. Year Issued: 2014
- **Antisense Oligonucleotide Against Human Ache and Uses thereof AS3 (EN101)**. United States. 7,456,154. 2006/02/01. Patent Status: Granted/Issued. Year Issued: 2008